Skip to main content

Versant Ventures — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

89
Companies
$4.4B
Total invested
$68.2M
Avg. check
24
Industries
Biotechnology 21Therapeutics 12Health Care 9Life Science 8Medical 8Pharmaceutical 5+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 89
Tentarix Biotherapeutics
September 2023

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.

Biotechnology · San Diego$35.0M Series B
Nexo Therapeutics
July 2023

Nexo Therapeutics offers treatments for some of cancer's most intractable targets.

Biotechnology · Littleton$60.0M Series A
Abdera Therapeutics
April 2023

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.

Biotechnology · Vancouver$142.0M Series B
Light Horse Therapeutics
January 2025

Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.

Biotechnology · San Diego$62.0M Series A
Monte Rosa Therapeutics
January 2026

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.

Biotechnology · Basel$300.0M Post-IPO Equity
Belharra Therapeutics
January 2023

Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.

Biotechnology · San Diego$50.0M Series A
Antag Therapeutics
December 2024

Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.

Biotechnology · Copenhagen$84.1M Series A
Launchpad Therapeutics
December 2022

Launchpad Therapeutics operates as an antibody-focused precision oncology company.

Life Science · San Francisco$10.0M Venture - Series Unknown
CODA Biotherapeutics
December 2021

CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.

Biotechnology · South San Francisco$28.0M Venture - Series Unknown
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post-IPO Equity
iECURE
November 2022

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Biotechnology · Philadelphia$65.0M Series A
Dayra Therapeutics
November 2025

Dayra Therapeutics manufactures peptide based medicines.

Health Care · Cambridge$20.0M Venture - Series Unknown
Halio
November 2023

Halio is developing adaptive, dynamic glass for the commercial, residential, and automotive markets.

Advanced Materials · Hayward$70.0M Corporate Round
Jnana Therapeutics
November 2022

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Biotechnology · Boston$107.0M Series C
Gate Bioscience
November 2025

Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.

Biotechnology · Brisbane$65.0M Series B
Nested Therapeutics
October 2022

Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations.

Biotechnology · Cambridge$90.0M Series A
Repare Therapeutics
October 2021

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

Biotechnology · Saint Laurent$101.2M Post-IPO Equity
Anokion
October 2022

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

Biotechnology · Ecublens$35.0M Venture - Series Unknown
Dualitas Therapeutics
September 2025

Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders

Biotechnology · San Francisco$65.0M Series A
AllRock Bio
September 2025

AllRock Bio is a drug developing firm that offers novel therapies to patients suffering hypertension and other fibrotic conditions.

Biotechnology · Boston$50.0M Series A
Granite Bio
April 2025

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

Biotechnology · Basel$70.0M Series B
Helicore Biopharma
January 2025

Helicore Biopharma is a biopharmaceutical company that discovers and develops novel weight-loss therapeutics.

Biopharma · San Mateo$65.0M Series A
Borealis Biosciences
December 2024

Borealis Biosciences is a company in the field of next-generation RNA medicines.

Biotechnology · Vancouver$30.0M Series A
858 Therapeutics
September 2024

858 Therapeutics develops small molecule drugs targeting oncology and immunology.

Biotechnology · San Diego$50.0M Series B

Where Versant Ventures invests

Biotechnology21
Therapeutics12
Health Care9
Life Science8
Medical8
Pharmaceutical5

About Versant Ventures's portfolio

How many companies has Versant Ventures invested in?▸

Versant Ventures has invested in 89 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Versant Ventures invest in?▸

Versant Ventures's top investment sectors include Biotechnology, Therapeutics, Health Care, Life Science, Medical. The firm invests across 24 different industry categories.

What is Versant Ventures's largest investment?▸

Among tracked funding rounds, Monte Rosa Therapeutics received $300.0M in a Post-IPO Equity round. Versant Ventures's total known invested capital is $4.4B.

What is the average investment size for Versant Ventures?▸

Versant Ventures's average investment size is $68.2M across its portfolio of 89 companies.

What are Versant Ventures's most recent investments?▸

Recent Versant Ventures portfolio additions include Tentarix Biotherapeutics, Nexo Therapeutics, Abdera Therapeutics, Light Horse Therapeutics, Monte Rosa Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 89 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →